Clinical trials of therapies for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis suffer from a lack of ...
CHICAGO — Alcohol-related cirrhosis carries a twofold higher mortality risk than cirrhosis stemming from metabolic ...
Originally linked to alcohol and caloric excess, fatty liver disease has evolved in classification. The redefinition of NAFLD to MASLD reflects its metabolic roots. MASH—marked by inflammation, ...
Please provide your email address to receive an email when new articles are posted on . A study of more than 1,300 women demonstrated that HIV is an independent risk factor for nonalcoholic ...
On Friday, the FDA granted accelerated approval to Novo Nordisk’s Wegovy for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis but without ...
In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...
Although semaglutide (Ozempic) missed its mark in improving liver fibrosis for patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis, improvements were noted in cardiometabolic ...
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results